Exact Mass: 723.5202623999999

PC(14:1(9Z)/18:4(6Z,9Z,12Z,15Z))

C40H70NO8P (723.483879)

PC(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(14:1(9Z)/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of myristoleic acid at the C-1 position and one chain of stearidonic acid at the C-2 position. The myristoleic acid moiety is derived from milk fats, while the stearidonic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC.

PC(18:4(6Z,9Z,12Z,15Z)/14:1(9Z))

C40H70NO8P (723.483879)

PC(18:4(6Z,9Z,12Z,15Z)/14:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:4(6Z,9Z,12Z,15Z)/14:1(9Z)), in particular, consists of one chain of stearidonic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. The stearidonic acid moiety is derived from seed oils, while the myristoleic acid moiety is derived from milk fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. PC(18:4(6Z,9Z,12Z,15Z)/14:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(18:4(6Z,9Z,12Z,15Z)/14:1(9Z)), in particular, consists of one chain of stearidonic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. The stearidonic acid moiety is derived from seed oils, while the myristoleic acid moiety is derived from milk fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(15:0/20:5(5Z,8Z,11Z,14Z,17Z))

C40H70NO8P (723.483879)

PE(15:0/20:5(5Z,8Z,11Z,14Z,17Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(15:0/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of eicosapentaenoic acid at the C-2 position. The pentadecanoic acid moiety is derived from dairy products and milk fat, while the eicosapentaenoic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS.

PE(18:3(6Z,9Z,12Z)/P-18:1(11Z))

C41H74NO7P (723.5202623999999)

PE(18:3(6Z,9Z,12Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:3(6Z,9Z,12Z)/P-18:1(11Z)), in particular, consists of one chain of g-linolenic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The g-linolenic acid moiety is derived from animal fats, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(18:3(6Z,9Z,12Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:3(6Z,9Z,12Z)/P-18:1(11Z)), in particular, consists of one chain of g-linolenic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The g-linolenic acid moiety is derived from animal fats, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(18:3(6Z,9Z,12Z)/P-18:1(9Z))

C41H74NO7P (723.5202623999999)

PE(18:3(6Z,9Z,12Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:3(6Z,9Z,12Z)/P-18:1(9Z)), in particular, consists of one chain of g-linolenic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The g-linolenic acid moiety is derived from animal fats, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(18:3(6Z,9Z,12Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:3(6Z,9Z,12Z)/P-18:1(9Z)), in particular, consists of one chain of g-linolenic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The g-linolenic acid moiety is derived from animal fats, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(18:3(9Z,12Z,15Z)/P-18:1(11Z))

C41H74NO7P (723.5202623999999)

PE(18:3(9Z,12Z,15Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:3(9Z,12Z,15Z)/P-18:1(11Z)), in particular, consists of one chain of a-linolenic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(18:3(9Z,12Z,15Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:3(9Z,12Z,15Z)/P-18:1(11Z)), in particular, consists of one chain of a-linolenic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(18:3(9Z,12Z,15Z)/P-18:1(9Z))

C41H74NO7P (723.5202623999999)

PE(18:3(9Z,12Z,15Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:3(9Z,12Z,15Z)/P-18:1(9Z)), in particular, consists of one chain of a-linolenic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(18:3(9Z,12Z,15Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:3(9Z,12Z,15Z)/P-18:1(9Z)), in particular, consists of one chain of a-linolenic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(18:4(6Z,9Z,12Z,15Z)/P-18:0)

C41H74NO7P (723.5202623999999)

PE(18:4(6Z,9Z,12Z,15Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:4(6Z,9Z,12Z,15Z)/P-18:0), in particular, consists of one chain of stearidonic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The stearidonic acid moiety is derived from seed oils, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(18:4(6Z,9Z,12Z,15Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(18:4(6Z,9Z,12Z,15Z)/P-18:0), in particular, consists of one chain of stearidonic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The stearidonic acid moiety is derived from seed oils, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(20:4(5Z,8Z,11Z,14Z)/P-16:0)

C41H74NO7P (723.5202623999999)

PE(20:4(5Z,8Z,11Z,14Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:4(5Z,8Z,11Z,14Z)/P-16:0), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The arachidonic acid moiety is derived from animal fats and eggs, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PE(20:4(8Z,11Z,14Z,17Z)/P-16:0)

C41H74NO7P (723.5202623999999)

PE(20:4(8Z,11Z,14Z,17Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:4(8Z,11Z,14Z,17Z)/P-16:0), in particular, consists of one chain of eicsoatetraenoic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The eicsoatetraenoic acid moiety is derived from fish oils, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(20:4(8Z,11Z,14Z,17Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:4(8Z,11Z,14Z,17Z)/P-16:0), in particular, consists of one chain of eicsoatetraenoic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The eicsoatetraenoic acid moiety is derived from fish oils, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(20:5(5Z,8Z,11Z,14Z,17Z)/15:0)

C40H70NO8P (723.483879)

PE(20:5(5Z,8Z,11Z,14Z,17Z)/15:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:5(5Z,8Z,11Z,14Z,17Z)/15:0), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position and one chain of pentadecanoic acid at the C-2 position. The eicosapentaenoic acid moiety is derived from fish oils, liver and kidney, while the pentadecanoic acid moiety is derived from dairy products and milk fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. PE(20:5(5Z,8Z,11Z,14Z,17Z)/15:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:5(5Z,8Z,11Z,14Z,17Z)/15:0), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position and one chain of pentadecanoic acid at the C-2 position. The eicosapentaenoic acid moiety is derived from fish oils, liver and kidney, while the pentadecanoic acid moiety is derived from dairy products and milk fat. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(P-16:0/20:4(5Z,8Z,11Z,14Z))

C41H74NO7P (723.5202623999999)

PE(P-16:0/20:4(5Z,8Z,11Z,14Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of arachidonic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the arachidonic acid moiety is derived from animal fats and eggs. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PE(P-16:0/20:4(8Z,11Z,14Z,17Z))

C41H74NO7P (723.5202623999999)

PE(P-16:0/20:4(8Z,11Z,14Z,17Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of eicsoatetraenoic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the eicsoatetraenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-16:0/20:4(8Z,11Z,14Z,17Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of eicsoatetraenoic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the eicsoatetraenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(P-18:0/18:4(6Z,9Z,12Z,15Z))

C41H74NO7P (723.5202623999999)

PE(P-18:0/18:4(6Z,9Z,12Z,15Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of stearidonic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the stearidonic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:0/18:4(6Z,9Z,12Z,15Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of stearidonic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the stearidonic acid moiety is derived from seed oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(P-18:1(11Z)/18:3(6Z,9Z,12Z))

C41H74NO7P (723.5202623999999)

PE(P-18:1(11Z)/18:3(6Z,9Z,12Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/18:3(6Z,9Z,12Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of g-linolenic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the g-linolenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:1(11Z)/18:3(6Z,9Z,12Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/18:3(6Z,9Z,12Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of g-linolenic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the g-linolenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(P-18:1(11Z)/18:3(9Z,12Z,15Z))

C41H74NO7P (723.5202623999999)

PE(P-18:1(11Z)/18:3(9Z,12Z,15Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/18:3(9Z,12Z,15Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of a-linolenic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.

PE(P-18:1(9Z)/18:3(6Z,9Z,12Z))

C41H74NO7P (723.5202623999999)

PE(P-18:1(9Z)/18:3(6Z,9Z,12Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/18:3(6Z,9Z,12Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of g-linolenic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the g-linolenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:1(9Z)/18:3(6Z,9Z,12Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/18:3(6Z,9Z,12Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of g-linolenic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the g-linolenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE(P-18:1(9Z)/18:3(9Z,12Z,15Z))

C41H74NO7P (723.5202623999999)

PE(P-18:1(9Z)/18:3(9Z,12Z,15Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/18:3(9Z,12Z,15Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of a-linolenic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:1(9Z)/18:3(9Z,12Z,15Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/18:3(9Z,12Z,15Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of a-linolenic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.

PE-NMe(14:0/20:5(5Z,8Z,11Z,14Z,17Z))

C40H70NO8P (723.483879)

PE-NMe(14:0/20:5(5Z,8Z,11Z,14Z,17Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(14:0/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of myristic acid at the C-1 position and one chain of eicosapentaenoic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

PE-NMe(14:1(9Z)/20:4(5Z,8Z,11Z,14Z))

C40H70NO8P (723.483879)

PE-NMe(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(14:1(9Z)/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of myristoleic acid at the C-1 position and one chain of arachidonic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

PE-NMe(14:1(9Z)/20:4(8Z,11Z,14Z,17Z))

C40H70NO8P (723.483879)

PE-NMe(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(14:1(9Z)/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of myristoleic acid at the C-1 position and one chain of eicosatetraenoic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

PE-NMe(16:1(9Z)/18:4(6Z,9Z,12Z,15Z))

C40H70NO8P (723.483879)

PE-NMe(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(16:1(9Z)/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of palmitoleic acid at the C-1 position and one chain of stearidonic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

PE-NMe(18:4(6Z,9Z,12Z,15Z)/16:1(9Z))

C40H70NO8P (723.483879)

PE-NMe(18:4(6Z,9Z,12Z,15Z)/16:1(9Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(18:4(6Z,9Z,12Z,15Z)/16:1(9Z)), in particular, consists of one chain of stearidonic acid at the C-1 position and one chain of palmitoleic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

PE-NMe(20:4(5Z,8Z,11Z,14Z)/14:1(9Z))

C40H70NO8P (723.483879)

PE-NMe(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(20:4(5Z,8Z,11Z,14Z)/14:1(9Z)), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

PE-NMe(20:4(8Z,11Z,14Z,17Z)/14:1(9Z))

C40H70NO8P (723.483879)

PE-NMe(20:4(8Z,11Z,14Z,17Z)/14:1(9Z)) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(20:4(8Z,11Z,14Z,17Z)/14:1(9Z)), in particular, consists of one chain of eicosatetraenoic acid at the C-1 position and one chain of myristoleic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

PE-NMe(20:5(5Z,8Z,11Z,14Z,17Z)/14:0)

C40H70NO8P (723.483879)

PE-NMe(20:5(5Z,8Z,11Z,14Z,17Z)/14:0) is a monomethylphosphatidylethanolamine. It is a glycerophospholipid, and it is formed by sequential methylation of phosphatidylethanolamine as part of a mechanism for biosynthesis of phosphatidylcholine. Monomethylphosphatidylethanolamines are usually found at trace levels in animal or plant tissues. They can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PE-NMe(20:5(5Z,8Z,11Z,14Z,17Z)/14:0), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position and one chain of myristic acid at the C-2 position. Fatty acids containing 16, 18 and 20 carbons are the most common. Phospholipids are ubiquitous in nature. They are key components of the cell lipid bilayer and are involved in metabolism and signaling.

DG(14:0/LTE4/0:0)

C40H69NO8S (723.4743634)

DG(14:0/LTE4/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(14:0/LTE4/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(LTE4/14:0/0:0)

C40H69NO8S (723.4743634)

DG(LTE4/14:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(LTE4/14:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(14:0/0:0/LTE4)

C40H69NO8S (723.4743634)

DG(14:0/0:0/LTE4) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(LTE4/0:0/14:0)

C40H69NO8S (723.4743634)

DG(LTE4/0:0/14:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(i-14:0/LTE4/0:0)

C40H69NO8S (723.4743634)

DG(i-14:0/LTE4/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-14:0/LTE4/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(LTE4/i-14:0/0:0)

C40H69NO8S (723.4743634)

DG(LTE4/i-14:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(LTE4/i-14:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.

DG(i-14:0/0:0/LTE4)

C40H69NO8S (723.4743634)

DG(i-14:0/0:0/LTE4) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

DG(LTE4/0:0/i-14:0)

C40H69NO8S (723.4743634)

DG(LTE4/0:0/i-14:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.

Phosphatidylethanolamine alkenyl 16:0-20:4

C41H74NO7P (723.5202623999999)

(2-aminoethoxy)[3-[hexadec-1-en-1-yloxy]-2-[icosa-5.8.11.14-tetraenoyloxy]propoxy]phosphinic acid

C41H74NO7P (723.5202623999999)

bacteriohopane-31,32,33,34-tetrol-35-cyclitol

C41H73NO9 (723.5285048)

Lecithin

C40H70NO8P (723.483879)

PE(35:5)

C40H70NO8P (723.483879)

PE(36:4)

C41H74NO7P (723.5202623999999)

1-Eicsoate

C41H74NO7P (723.5202623999999)

PC(12:0/20:5(5Z,8Z,11Z,14Z,17Z))

C40H70NO8P (723.483879)

PC(20:5(5Z,8Z,11Z,14Z,17Z)/12:0)

C40H70NO8P (723.483879)

PE(15:1(9Z)/20:4(5Z,8Z,11Z,14Z))

C40H70NO8P (723.483879)

PE(17:1(9Z)/18:4(6Z,9Z,12Z,15Z))

C40H70NO8P (723.483879)

PE(17:2(9Z,12Z)/18:3(6Z,9Z,12Z))

C40H70NO8P (723.483879)

PE(17:2(9Z,12Z)/18:3(9Z,12Z,15Z))

C40H70NO8P (723.483879)

PE(18:3(6Z,9Z,12Z)/17:2(9Z,12Z))

C40H70NO8P (723.483879)

PE(18:3(9Z,12Z,15Z)/17:2(9Z,12Z))

C40H70NO8P (723.483879)

PE(18:4(6Z,9Z,12Z,15Z)/17:1(9Z))

C40H70NO8P (723.483879)

PE(20:4(5Z,8Z,11Z,14Z)/15:1(9Z))

C40H70NO8P (723.483879)

PE(O-16:0/20:5(5Z,8Z,11Z,14Z,17Z))

C41H74NO7P (723.5202623999999)

PC 32:5

C40H70NO8P (723.483879)

PE 35:5

C40H70NO8P (723.483879)

PE O-36:5

C41H74NO7P (723.5202623999999)

PE(P-18:1(11Z)/18:3(9Z,12Z,15Z))

C41H74NO7P (723.5202623999999)

DG(14:0/LTE4/0:0)

C40H69NO8S (723.4743634)

DG(LTE4/14:0/0:0)

C40H69NO8S (723.4743634)

DG(14:0/0:0/LTE4)

C40H69NO8S (723.4743634)

DG(LTE4/0:0/14:0)

C40H69NO8S (723.4743634)

DG(i-14:0/LTE4/0:0)

C40H69NO8S (723.4743634)

DG(LTE4/i-14:0/0:0)

C40H69NO8S (723.4743634)

DG(i-14:0/0:0/LTE4)

C40H69NO8S (723.4743634)

DG(LTE4/0:0/i-14:0)

C40H69NO8S (723.4743634)

2-azaniumylethyl (2R)-3-{[(1Z)-hexadec-1-en-1-yl]oxy}-2-{[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyl]oxy}propyl phosphate

C41H74NO7P (723.5202623999999)

1-O-(alpha-D-galactopyranosyl)-N-(11-phenylundecanoyl)phytosphingosine

C41H73NO9 (723.5285048)

A glycophytoceramide having an alpha-D-galactopyranosyl residue at the O-1 position and an 11-phenylundecanoyl group attached to the nitrogen.

2-[[(2S,3S,4R)-3,4-dihydroxy-2-(2-hydroxyhexadecanoylamino)-15-methylhexadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C38H80N2O8P+ (723.5651990000001)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C41H74NO7P (723.5202623999999)

Ldgcc 34:9

C44H69NO7 (723.5073763999999)

HexCer 29:3;2O/7:0

C42H77NO8 (723.5648882)

HexCer 28:3;2O/8:0

C42H77NO8 (723.5648882)

HexCer 8:0;2O/28:3

C42H77NO8 (723.5648882)

HexCer 27:3;2O/9:0

C42H77NO8 (723.5648882)

HexCer 33:3;2O/3:0

C42H77NO8 (723.5648882)

HexCer 30:3;2O/6:0

C42H77NO8 (723.5648882)

HexCer 8:1;2O/28:2

C42H77NO8 (723.5648882)

HexCer 31:3;2O/5:0

C42H77NO8 (723.5648882)

HexCer 32:3;2O/4:0

C42H77NO8 (723.5648882)

HexCer 34:3;2O/2:0

C42H77NO8 (723.5648882)

HexCer 14:1;2O/22:2

C42H77NO8 (723.5648882)

HexCer 26:3;2O/10:0

C42H77NO8 (723.5648882)

HexCer 19:2;2O/17:1

C42H77NO8 (723.5648882)

HexCer 18:1;2O/18:2

C42H77NO8 (723.5648882)

HexCer 18:0;2O/18:3

C42H77NO8 (723.5648882)

HexCer 17:1;2O/19:2

C42H77NO8 (723.5648882)

HexCer 15:1;2O/21:2

C42H77NO8 (723.5648882)

HexCer 15:2;2O/21:1

C42H77NO8 (723.5648882)

HexCer 12:2;2O/24:1

C42H77NO8 (723.5648882)

HexCer 10:1;2O/26:2

C42H77NO8 (723.5648882)

HexCer 20:2;2O/16:1

C42H77NO8 (723.5648882)

HexCer 20:0;2O/16:3

C42H77NO8 (723.5648882)

HexCer 10:0;2O/26:3

C42H77NO8 (723.5648882)

HexCer 12:1;2O/24:2

C42H77NO8 (723.5648882)

HexCer 19:1;2O/17:2

C42H77NO8 (723.5648882)

HexCer 14:0;2O/22:3

C42H77NO8 (723.5648882)

HexCer 20:1;2O/16:2

C42H77NO8 (723.5648882)

HexCer 12:0;2O/24:3

C42H77NO8 (723.5648882)

HexCer 23:2;2O/13:1

C42H77NO8 (723.5648882)

HexCer 14:2;2O/22:1

C42H77NO8 (723.5648882)

HexCer 25:3;2O/11:0

C42H77NO8 (723.5648882)

HexCer 18:2;2O/18:1

C42H77NO8 (723.5648882)

HexCer 16:0;2O/20:3

C42H77NO8 (723.5648882)

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (21Z,24Z,27Z,30Z,33Z)-hexatriaconta-21,24,27,30,33-pentaenoate

C41H74NO7P (723.5202623999999)

Lnape 9:0/N-26:5

C40H70NO8P (723.483879)

Lnape 26:5/N-9:0

C40H70NO8P (723.483879)

HexCer 16:3;2O/19:1;O

C41H73NO9 (723.5285048)

HexCer 20:3;2O/15:1;O

C41H73NO9 (723.5285048)

[3-nonoxy-2-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

HexCer 22:3;2O/13:1;O

C41H73NO9 (723.5285048)

HexCer 19:3;2O/16:1;O

C41H73NO9 (723.5285048)

HexCer 18:3;2O/17:1;O

C41H73NO9 (723.5285048)

HexCer 21:3;2O/14:1;O

C41H73NO9 (723.5285048)

HexCer 17:3;2O/18:1;O

C41H73NO9 (723.5285048)

HexCer 17:2;2O/18:2;O

C41H73NO9 (723.5285048)

HexCer 19:2;2O/16:2;O

C41H73NO9 (723.5285048)

2-[3-octanoyloxy-2-[(13Z,16Z)-tetracosa-13,16-dienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H77NO8 (723.5648882)

Lnape 22:5/N-13:0

C40H70NO8P (723.483879)

Lnape 18:3/N-17:2

C40H70NO8P (723.483879)

Lnape 13:0/N-22:5

C40H70NO8P (723.483879)

Lnape 15:1/N-20:4

C40H70NO8P (723.483879)

Lnape 18:4/N-17:1

C40H70NO8P (723.483879)

Lnape 17:1/N-18:4

C40H70NO8P (723.483879)

Lnape 13:1/N-22:4

C40H70NO8P (723.483879)

Lnape 24:5/N-11:0

C40H70NO8P (723.483879)

Lnape 11:0/N-24:5

C40H70NO8P (723.483879)

Lnape 20:4/N-15:1

C40H70NO8P (723.483879)

Lnape 15:0/N-20:5

C40H70NO8P (723.483879)

Lnape 17:2/N-18:3

C40H70NO8P (723.483879)

Lnape 16:3/N-19:2

C40H70NO8P (723.483879)

Lnape 19:2/N-16:3

C40H70NO8P (723.483879)

Lnape 20:5/N-15:0

C40H70NO8P (723.483879)

Lnape 22:4/N-13:1

C40H70NO8P (723.483879)

2-[3-decanoyloxy-2-[(13Z,16Z)-docosa-13,16-dienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H77NO8 (723.5648882)

2-[2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxy-3-undecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H77NO8 (723.5648882)

2-[3-dodecanoyloxy-2-[(11Z,14Z)-icosa-11,14-dienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H77NO8 (723.5648882)

2-[2-[(Z)-octadec-9-enoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H77NO8 (723.5648882)

2-[2,3-bis[[(Z)-hexadec-9-enoyl]oxy]propoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H77NO8 (723.5648882)

2-[2-[(Z)-nonadec-9-enoyl]oxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H77NO8 (723.5648882)

2-[2-[(Z)-heptadec-9-enoyl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H77NO8 (723.5648882)

2-[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-hexadecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H77NO8 (723.5648882)

2-[2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-tetradecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H77NO8 (723.5648882)

2-[2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxy-3-tridecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H77NO8 (723.5648882)

2-[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-pentadecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate

C42H77NO8 (723.5648882)

HexCer 18:3;3O/16:2;(2OH)

C40H69NO10 (723.4921214)

(4E,8E)-3-hydroxy-2-[[(14Z,16Z)-2-hydroxydocosa-14,16-dienoyl]amino]icosa-4,8-diene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxynonadec-9-enoyl]amino]tricosa-4,8,12-triene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxyhexadec-7-enoyl]amino]hexacosa-4,8,12-triene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxyhenicos-9-enoyl]amino]henicosa-4,8,12-triene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

(4E,8E)-3-hydroxy-2-[[(4Z,7Z)-2-hydroxyhexadeca-4,7-dienoyl]amino]hexacosa-4,8-diene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoxy]propan-2-yl] octanoate

C41H74NO7P (723.5202623999999)

(4E,8E)-3-hydroxy-2-[[(11Z,14Z)-2-hydroxyicosa-11,14-dienoyl]amino]docosa-4,8-diene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

(4E,8E)-3-hydroxy-2-[[(11Z,14Z)-2-hydroxyhexacosa-11,14-dienoyl]amino]hexadeca-4,8-diene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] (13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoate

C41H74NO7P (723.5202623999999)

(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxyoctadec-11-enoyl]amino]tetracosa-4,8,12-triene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxypentacos-11-enoyl]amino]heptadeca-4,8,12-triene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxyhexacos-11-enoyl]amino]hexadeca-4,8,12-triene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxytetracos-11-enoyl]amino]octadeca-4,8,12-triene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

(4E,8E)-3-hydroxy-2-[[(10Z,12Z)-2-hydroxyoctadeca-10,12-dienoyl]amino]tetracosa-4,8-diene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxytricos-11-enoyl]amino]nonadeca-4,8,12-triene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxydocos-11-enoyl]amino]icosa-4,8,12-triene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

(4E,8E)-3-hydroxy-2-[[(18Z,21Z)-2-hydroxytetracosa-18,21-dienoyl]amino]octadeca-4,8-diene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxyicos-11-enoyl]amino]docosa-4,8,12-triene-1-sulfonic acid

C42H77NO6S (723.5471302000001)

[2-nonanoyloxy-3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

[2-heptanoyloxy-3-[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

[3-[(13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoxy]-2-pentanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

(4E,8E,12E)-2-[[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]amino]-3-hydroxyoctadeca-4,8,12-triene-1-sulfonic acid

C44H69NO5S (723.4896183999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] (11Z,14Z)-icosa-11,14-dienoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoxy]propan-2-yl] decanoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] (Z)-icos-11-enoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoxy]propan-2-yl] dodecanoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] (11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-icos-11-enoxy]propan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C41H74NO7P (723.5202623999999)

[3-[(Z)-heptadec-9-enoxy]-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-tridecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-pentadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

[2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

[2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-undecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

[2-[(Z)-heptadec-9-enoyl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

[2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(Z)-pentadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

2-[4-(12-hydroxy-10,13-dimethyl-3-pentadecanoyloxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoylamino]ethanesulfonic acid

C41H73NO7S (723.5107467999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] (9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoate

C40H70NO8P (723.483879)

HexCer 21:3;2O/15:0

C42H77NO8 (723.5648882)

HexCer 23:3;2O/13:0

C42H77NO8 (723.5648882)

HexCer 17:2;2O/19:1

C42H77NO8 (723.5648882)

HexCer 16:1;2O/20:2

C42H77NO8 (723.5648882)

HexCer 15:3;2O/21:0

C42H77NO8 (723.5648882)

HexCer 16:2;2O/20:1

C42H77NO8 (723.5648882)

HexCer 22:3;2O/14:0

C42H77NO8 (723.5648882)

HexCer 14:3;2O/22:0

C42H77NO8 (723.5648882)

HexCer 24:3;2O/12:0

C42H77NO8 (723.5648882)

HexCer 20:3;2O/16:0

C42H77NO8 (723.5648882)

HexCer 16:3;2O/20:0

C42H77NO8 (723.5648882)

HexCer 22:2;2O/14:1

C42H77NO8 (723.5648882)

HexCer 18:3;2O/18:0

C42H77NO8 (723.5648882)

HexCer 19:3;2O/17:0

C42H77NO8 (723.5648882)

HexCer 21:2;2O/15:1

C42H77NO8 (723.5648882)

HexCer 17:3;2O/19:0

C42H77NO8 (723.5648882)

CerP 18:0;2O/24:4

C42H78NO6P (723.5566457999998)

4-[3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

4-[3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]propan-2-yl] tetradecanoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] (Z)-hexadec-9-enoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]propan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C41H74NO7P (723.5202623999999)

[3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]-2-undecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]propan-2-yl] (Z)-tetradec-9-enoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C41H74NO7P (723.5202623999999)

[3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]-2-pentadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] (Z)-octadec-9-enoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octadecoxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C41H74NO7P (723.5202623999999)

[3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]-2-[(Z)-pentadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octadec-9-enoxy]propan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] octadecanoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C41H74NO7P (723.5202623999999)

[3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]-2-tridecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]propan-2-yl] hexadecanoate

C41H74NO7P (723.5202623999999)

[3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C41H74NO7P (723.5202623999999)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecoxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C41H74NO7P (723.5202623999999)

[3-octanoyloxy-2-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] (11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoate

C40H70NO8P (723.483879)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecanoyloxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C40H70NO8P (723.483879)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C40H70NO8P (723.483879)

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropyl] (9Z,12Z)-nonadeca-9,12-dienoate

C40H70NO8P (723.483879)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C40H70NO8P (723.483879)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C40H70NO8P (723.483879)

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropyl] (Z)-nonadec-9-enoate

C40H70NO8P (723.483879)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C40H70NO8P (723.483879)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C40H70NO8P (723.483879)

[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoyl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C40H70NO8P (723.483879)

(4Z,7Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicos-4-en-2-yl]hexadeca-4,7-dienamide

C42H77NO8 (723.5648882)

[3-dodecanoyloxy-2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradeca-4,8-dien-2-yl]docos-11-enamide

C42H77NO8 (723.5648882)

(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadeca-4,8-dien-2-yl]henicos-9-enamide

C42H77NO8 (723.5648882)

[2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

(10Z,12Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]octadeca-10,12-dienamide

C42H77NO8 (723.5648882)

(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytricosa-4,8-dien-2-yl]tridec-8-enamide

C42H77NO8 (723.5648882)

(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]octadec-11-enamide

C42H77NO8 (723.5648882)

(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetracosa-4,8-dien-2-yl]dodec-5-enamide

C42H77NO8 (723.5648882)

(14Z,16Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradec-4-en-2-yl]docosa-14,16-dienamide

C42H77NO8 (723.5648882)

(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-4,8-dien-2-yl]hexadec-7-enamide

C42H77NO8 (723.5648882)

[3-decanoyloxy-2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

[3-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(Z)-hexadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyhenicosan-2-yl]propanamide

C36H69NO13 (723.4768664)

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytetradecan-2-yl]decanamide

C36H69NO13 (723.4768664)

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynonan-2-yl]pentadecanamide

C36H69NO13 (723.4768664)

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyhexadecan-2-yl]octanamide

C36H69NO13 (723.4768664)

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyoctan-2-yl]hexadecanamide

C36H69NO13 (723.4768664)

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydodecan-2-yl]dodecanamide

C36H69NO13 (723.4768664)

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydecan-2-yl]tetradecanamide

C36H69NO13 (723.4768664)

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyheptadecan-2-yl]heptanamide

C36H69NO13 (723.4768664)

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxypentadecan-2-yl]nonanamide

C36H69NO13 (723.4768664)

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyicosan-2-yl]butanamide

C36H69NO13 (723.4768664)

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynonadecan-2-yl]pentanamide

C36H69NO13 (723.4768664)

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydocosan-2-yl]acetamide

C36H69NO13 (723.4768664)

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytridecan-2-yl]undecanamide

C36H69NO13 (723.4768664)

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyoctadecan-2-yl]hexanamide

C36H69NO13 (723.4768664)

N-[1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyundecan-2-yl]tridecanamide

C36H69NO13 (723.4768664)

[(2S,3R)-3-hydroxy-2-[[(5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoyl]amino]octadecyl] dihydrogen phosphate

C42H78NO6P (723.5566457999998)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C40H70NO8P (723.483879)

4-[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

[(2R)-3-dodecanoyloxy-2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

4-[3-[(7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoyl]oxy-2-[(E)-dodec-5-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

[3-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

4-[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(6E,9E,12E,15E,18E,21E)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

(E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadeca-4,8-dien-2-yl]heptadec-9-enamide

C42H77NO8 (723.5648882)

(9E,12E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]octadeca-9,12-dienamide

C42H77NO8 (723.5648882)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9E,12E)-heptadeca-9,12-dienoyl]oxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C40H70NO8P (723.483879)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C41H74NO7P (723.5202623999999)

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

4-[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

(E)-N-[(2S,3R,4E,6E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadeca-4,6-dien-2-yl]icos-11-enamide

C42H77NO8 (723.5648882)

[(2R)-3-decanoyloxy-2-[(4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

4-[2-[(7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoyl]oxy-3-[(E)-dodec-5-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

4-[2-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-[(6E,9E)-dodeca-6,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C40H70NO8P (723.483879)

(E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadeca-4,8-dien-2-yl]icos-11-enamide

C42H77NO8 (723.5648882)

4-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

4-[2-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-heptadec-9-enoyl]oxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C40H70NO8P (723.483879)

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(E)-hexadec-7-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

4-[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

4-[3-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-2-[(6E,9E)-dodeca-6,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(E)-heptadec-9-enoyl]oxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C40H70NO8P (723.483879)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-hexadec-1-enoxy]propan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C41H74NO7P (723.5202623999999)

[(2S)-2-decanoyloxy-3-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

4-[2-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[(6E,9E,12E,15E,18E,21E)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C40H70NO8P (723.483879)

[(2R)-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropyl] nonadecanoate

C40H70NO8P (723.483879)

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

(E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-4,8-dien-2-yl]hexadec-9-enamide

C42H77NO8 (723.5648882)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9E,12E)-heptadeca-9,12-dienoyl]oxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C40H70NO8P (723.483879)

[(2S)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-pentadecanoyloxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C40H70NO8P (723.483879)

4-[3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

[(2R)-3-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

4-[2-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropyl] (7E,9E)-nonadeca-7,9-dienoate

C40H70NO8P (723.483879)

(E)-N-[(2S,3R,4E,6E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradeca-4,6-dien-2-yl]docos-13-enamide

C42H77NO8 (723.5648882)

[(2R)-3-decanoyloxy-2-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C40H70NO8P (723.483879)

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropyl] (E)-nonadec-9-enoate

C40H70NO8P (723.483879)

[(2S)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(E)-pentadec-9-enoyl]oxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C40H70NO8P (723.483879)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C40H70NO8P (723.483879)

[(2S)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-tridecanoyloxypropyl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C40H70NO8P (723.483879)

[(2S)-2-decanoyloxy-3-[(4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

(E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradeca-4,8-dien-2-yl]docos-13-enamide

C42H77NO8 (723.5648882)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-hexadec-1-enoxy]propan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C41H74NO7P (723.5202623999999)

4-[2-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C40H70NO8P (723.483879)

[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(4E,7E)-hexadeca-4,7-dienoyl]oxypropyl] (10E,13E,16E)-nonadeca-10,13,16-trienoate

C40H70NO8P (723.483879)

[(2S)-2-dodecanoyloxy-3-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

4-[2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

4-[3-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-2-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

4-[3-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-2-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

4-[3-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxy-2-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-heptadec-9-enoyl]oxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C40H70NO8P (723.483879)

[(2R)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(E)-heptadec-9-enoyl]oxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C40H70NO8P (723.483879)

(E)-N-[(2S,3R,4E,14E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,14-dien-2-yl]octadec-9-enamide

C42H77NO8 (723.5648882)

[3-hexadecanoyloxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C40H70NO8P (723.483879)

4-[3-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxy-2-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

[(2S)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(E)-pentadec-9-enoyl]oxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C40H70NO8P (723.483879)

(9E,12E)-N-[(E,2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-8-en-2-yl]octadeca-9,12-dienamide

C42H77NO8 (723.5648882)

(E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]octadec-9-enamide

C42H77NO8 (723.5648882)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C41H74NO7P (723.5202623999999)

[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C40H70NO8P (723.483879)

[(2S)-3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-tridecanoyloxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C40H70NO8P (723.483879)

4-[3-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-2-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate

C44H69NO7 (723.5073763999999)

2-[[(4E,8E,12E)-2-[[(4Z,7Z)-hexadeca-4,7-dienoyl]amino]-3-hydroxyicosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(10Z,12Z)-octadeca-10,12-dienoyl]amino]octadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(11Z,14Z)-icosa-11,14-dienoyl]amino]hexadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[[(4E,8E,12E)-2-[[(14Z,16Z)-docosa-14,16-dienoyl]amino]-3-hydroxytetradeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[hydroxy-[3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]octadecoxy]phosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]amino]dodeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]amino]hexadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[[(E)-2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxyicos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[[(E)-2-[[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]amino]-3-hydroxydec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[[(4E,8E)-2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxyicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[[2-[[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoyl]amino]-3-hydroxydecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[hydroxy-[3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]hexadecoxy]phosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]octadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]amino]octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[hydroxy-[(E)-3-hydroxy-2-[[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]amino]dodec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(9Z,12Z)-nonadeca-9,12-dienoyl]amino]heptadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[[(4E,8E,12E)-2-[[(13Z,16Z)-docosa-13,16-dienoyl]amino]-3-hydroxytetradeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[hydroxy-[(E)-3-hydroxy-2-[[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]amino]hexadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[[(E)-2-[[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]amino]-3-hydroxytetradec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[[(4E,8E,12E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxynonadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[hydroxy-[3-hydroxy-2-[[(13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoyl]amino]octoxy]phosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[[(4E,8E,12E)-2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxyicosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[hydroxy-[3-hydroxy-2-[[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]amino]dodecoxy]phosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[[(4E,8E,12E)-2-[[(11Z,14Z)-henicosa-11,14-dienoyl]amino]-3-hydroxypentadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[[2-[[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]amino]-3-hydroxytetradecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[hydroxy-[(E)-3-hydroxy-2-[[(16Z,19Z,22Z,25Z)-octacosa-16,19,22,25-tetraenoyl]amino]oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[[(4E,8E)-2-[[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]amino]-3-hydroxytetradeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

2-[hydroxy-[(E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium

C41H76N2O6P+ (723.5440705999999)

1-(1Z-Hexadecenyl)-2-arachidonoyl-sn-glycero-3-phosphoethanolamine

C41H74NO7P (723.5202623999999)

A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alkenyl and acyl groups are specified as (1Z)-hexadecenyl and arachidonoyl respectively.

PE(P-18:1(11Z)/18:3(6Z,9Z,12Z))

C41H74NO7P (723.5202623999999)

PE(P-18:0/18:4(6Z,9Z,12Z,15Z))

C41H74NO7P (723.5202623999999)

PC(18:4(6Z,9Z,12Z,15Z)/14:1(9Z))

C40H70NO8P (723.483879)

PE(P-16:0/20:4(8Z,11Z,14Z,17Z))

C41H74NO7P (723.5202623999999)

PE(P-18:1(9Z)/18:3(6Z,9Z,12Z))

C41H74NO7P (723.5202623999999)

PE(P-18:1(9Z)/18:3(9Z,12Z,15Z))

C41H74NO7P (723.5202623999999)

PE(18:3(6Z,9Z,12Z)/P-18:1(11Z))

C41H74NO7P (723.5202623999999)

PE(18:3(6Z,9Z,12Z)/P-18:1(9Z))

C41H74NO7P (723.5202623999999)

PE(18:3(9Z,12Z,15Z)/P-18:1(9Z))

C41H74NO7P (723.5202623999999)

PE(18:4(6Z,9Z,12Z,15Z)/P-18:0)

C41H74NO7P (723.5202623999999)

PE(20:4(5Z,8Z,11Z,14Z)/P-16:0)

C41H74NO7P (723.5202623999999)

PE(20:4(8Z,11Z,14Z,17Z)/P-16:0)

C41H74NO7P (723.5202623999999)

PE(18:3(9Z,12Z,15Z)/P-18:1(11Z))

C41H74NO7P (723.5202623999999)

1-(1Z-hexadecenyl)-2-arachidonoyl-sn-glycero-3-phosphoethanolamine zwitterion

C41H74NO7P (723.5202623999999)

A 1-(Z)-alk-1-enyl-2-acyl-sn-glycero-3-phosphoethanolamine zwitterion in which the alk-1-enyl and acyl groups are specified as (1Z-hexadecenyl) and arachidonoyl respectively.

phosphatidylcholine 32:5

C40H70NO8P (723.483879)

A 1,2-diacyl-sn-glycero-3-phosphocholine in which the acyl groups at C-1 and C-2 contain 32 carbons in total with 5 double bonds.

phosphatidylethanolamine P-36:4

C41H74NO7P (723.5202623999999)

A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine zwitterion in which the alk-1-enyl and acyl groups at positions 1 and 2 contain 36 carbon atoms in total with 4 additional double bonds.

MePC(32:5)

C41H74NO7P (723.5202623999999)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

MePC(31:5)

C40H70NO8P (723.483879)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

Hex1Cer(36:3)

C42H77NO8 (723.5648882)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

DGCC 30:4;O2

C40H69NO10 (723.4921214)

DGCC 31:3;O

C41H73NO9 (723.5285048)

DGCC 32:2

C42H77NO8 (723.5648882)

DGCC 33:9

C43H65NO8 (723.470993)

DGTS 31:3;O2

C41H73NO9 (723.5285048)

DGTS 32:2;O

C42H77NO8 (723.5648882)

DGTS 33:9;O

C43H65NO8 (723.470993)

DGTS 34:8

C44H69NO7 (723.5073763999999)

PC O-33:5

C41H74NO7P (723.5202623999999)

PC P-33:4

C41H74NO7P (723.5202623999999)

PC P-33:4 or PC O-33:5

C41H74NO7P (723.5202623999999)

PC 10:0_22:5

C40H70NO8P (723.483879)

PC 12:0_20:5

C40H70NO8P (723.483879)

PC 14:1_18:4

C40H70NO8P (723.483879)

LNAPE 35:5

C40H70NO8P (723.483879)

PE O-14:0/22:5

C41H74NO7P (723.5202623999999)

PE O-14:1/22:4

C41H74NO7P (723.5202623999999)

PE O-16:0/20:5

C41H74NO7P (723.5202623999999)

PE O-16:1/20:4

C41H74NO7P (723.5202623999999)

PE O-16:2/20:3

C41H74NO7P (723.5202623999999)

PE O-18:1/18:4

C41H74NO7P (723.5202623999999)

PE O-18:2/18:3

C41H74NO7P (723.5202623999999)

PE P-14:0/22:4

C41H74NO7P (723.5202623999999)

PE P-14:0/22:4 or PE O-14:1/22:4

C41H74NO7P (723.5202623999999)

PE P-16:0/20:4

C41H74NO7P (723.5202623999999)

PE P-16:0/20:4 or PE O-16:1/20:4

C41H74NO7P (723.5202623999999)

PE P-16:1/20:3

C41H74NO7P (723.5202623999999)

PE P-16:1/20:3 or PE O-16:2/20:3

C41H74NO7P (723.5202623999999)

PE P-18:0/18:4

C41H74NO7P (723.5202623999999)

PE P-18:0/18:4 or PE O-18:1/18:4

C41H74NO7P (723.5202623999999)

PE P-18:1/18:3

C41H74NO7P (723.5202623999999)

PE P-18:1/18:3 or PE O-18:2/18:3

C41H74NO7P (723.5202623999999)

PE P-18:2/18:2

C41H74NO7P (723.5202623999999)

PE P-36:4

C41H74NO7P (723.5202623999999)

PE P-36:4 or PE O-36:5

C41H74NO7P (723.5202623999999)

PE 13:0_22:5

C40H70NO8P (723.483879)

PE 15:0_20:5

C40H70NO8P (723.483879)

PE 15:1_20:4

C40H70NO8P (723.483879)

PE 17:1_18:4

C40H70NO8P (723.483879)

PE 17:2_18:3

C40H70NO8P (723.483879)

CerP 16:2;O2/26:2

C42H78NO6P (723.5566457999998)

CerP 18:0;O2/24:4

C42H78NO6P (723.5566457999998)

CerP 20:0;O2/22:4

C42H78NO6P (723.5566457999998)

CerP 20:2;O2/22:2

C42H78NO6P (723.5566457999998)

CerP 22:0;O2/20:4

C42H78NO6P (723.5566457999998)

CerP 22:1;O2/20:3

C42H78NO6P (723.5566457999998)

CerP 22:2;O2/20:2

C42H78NO6P (723.5566457999998)

CerP 42:4;O2

C42H78NO6P (723.5566457999998)

Hex2Cer 14:0;O2/10:0

C36H69NO13 (723.4768664)

Hex2Cer 24:0;O2

C36H69NO13 (723.4768664)

LacCer 14:0;O2/10:0

C36H69NO13 (723.4768664)

LacCer 24:0;O2

C36H69NO13 (723.4768664)

GalCer 14:1;O2/22:2

C42H77NO8 (723.5648882)

GalCer 14:2;O2/22:1

C42H77NO8 (723.5648882)

GalCer 15:0;O3/20:4

C41H73NO9 (723.5285048)

GalCer 16:0;O2/20:3

C42H77NO8 (723.5648882)

GalCer 16:1;O2/20:2

C42H77NO8 (723.5648882)

GalCer 16:2;O2/20:1

C42H77NO8 (723.5648882)

GalCer 17:0;O3/18:4

C41H73NO9 (723.5285048)

GalCer 18:0;O2/18:3

C42H77NO8 (723.5648882)

GalCer 18:1;O2/18:2

C42H77NO8 (723.5648882)

GalCer 18:2;O2/18:1

C42H77NO8 (723.5648882)

GalCer 19:1;O2/17:2

C42H77NO8 (723.5648882)

GalCer 19:2;O2/17:1

C42H77NO8 (723.5648882)

GalCer 20:2;O2/16:1

C42H77NO8 (723.5648882)

GalCer 21:2;O2/15:1

C42H77NO8 (723.5648882)

GalCer 22:2;O2/14:1

C42H77NO8 (723.5648882)

GalCer 35:4;O3

C41H73NO9 (723.5285048)

GalCer 36:3;O2

C42H77NO8 (723.5648882)

GlcCer 14:1;O2/22:2

C42H77NO8 (723.5648882)

GlcCer 14:2;O2/22:1

C42H77NO8 (723.5648882)

GlcCer 15:0;O3/20:4

C41H73NO9 (723.5285048)

GlcCer 16:0;O2/20:3

C42H77NO8 (723.5648882)

GlcCer 16:1;O2/20:2

C42H77NO8 (723.5648882)

GlcCer 16:2;O2/20:1

C42H77NO8 (723.5648882)

GlcCer 17:0;O3/18:4

C41H73NO9 (723.5285048)

GlcCer 18:0;O2/18:3

C42H77NO8 (723.5648882)

GlcCer 18:1;O2/18:2

C42H77NO8 (723.5648882)

GlcCer 18:2;O2/18:1

C42H77NO8 (723.5648882)

GlcCer 19:1;O2/17:2

C42H77NO8 (723.5648882)

GlcCer 19:2;O2/17:1

C42H77NO8 (723.5648882)

GlcCer 20:2;O2/16:1

C42H77NO8 (723.5648882)

GlcCer 21:2;O2/15:1

C42H77NO8 (723.5648882)

GlcCer 22:2;O2/14:1

C42H77NO8 (723.5648882)

GlcCer 35:4;O3

C41H73NO9 (723.5285048)

GlcCer 36:3;O2

C42H77NO8 (723.5648882)

HexCer 14:1;O2/22:2

C42H77NO8 (723.5648882)

HexCer 14:2;O2/22:1

C42H77NO8 (723.5648882)

HexCer 15:0;O3/20:4

C41H73NO9 (723.5285048)

HexCer 16:0;O2/20:3

C42H77NO8 (723.5648882)

HexCer 16:1;O2/20:2

C42H77NO8 (723.5648882)

HexCer 16:2;O2/20:1

C42H77NO8 (723.5648882)

HexCer 17:0;O3/18:4

C41H73NO9 (723.5285048)

HexCer 18:0;O2/18:3

C42H77NO8 (723.5648882)

HexCer 18:1;O2/18:2

C42H77NO8 (723.5648882)

HexCer 18:2;O2/18:1

C42H77NO8 (723.5648882)

HexCer 19:1;O2/17:2

C42H77NO8 (723.5648882)

HexCer 19:2;O2/17:1

C42H77NO8 (723.5648882)

HexCer 20:2;O2/16:1

C42H77NO8 (723.5648882)

HexCer 21:2;O2/15:1

C42H77NO8 (723.5648882)

HexCer 22:2;O2/14:1

C42H77NO8 (723.5648882)

HexCer 35:4;O3

C41H73NO9 (723.5285048)

HexCer 36:3;O2

C42H77NO8 (723.5648882)

GDCAE 19:3

C45H73NO6 (723.5437597999999)

TDCAE 15:0

C41H73NO7S (723.5107467999999)

dMePE(34:5)

C41H74NO7P (723.5202623999999)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved